Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from.
30 stories
Medtronic said an expanded 510(k) clears its Hugo robot for upper abdominal general surgery, inguinal hernia and appendectomy, less than a year after its first U.S. clearance for urology. No gynecology decision has been announced.
Monograph Capital led the round for the Toronto company, which sells AI that tells drugmakers' sales and marketing teams which physicians to reach. PHM, part of Publicis Groupe, anchored the round and signed a platform agreement.
The Series A follows an $11.6 million raise reported in May. Knit says its Med-BEAM model learns from what clinicians actually do, and it plans to start with patient navigation, specialist routing, scheduling and hospital operations.
DCVC led the Series B for the San Francisco company, whose N1 System is built to run endovascular procedures on-site, remotely or autonomously. The money funds a planned pivotal trial across the University of California network.
Bracco and Avicenna.AI announced 510(k) clearances for two brain aneurysm programs that read head CT angiography scans, the first products in Bracco's UPTUNITY AI line. Avicenna.AI will lead U.S. sales.
Most buyers took pre-funded warrants instead of shares, plus common warrants on top. The raise follows a May recall of InspireMD's CGuard Prime systems with 135 cm delivery systems.
Savant Growth led the Series A for the Scottsdale, Ariz., company, which two physicians started in 2015. XpertDox says its software codes over 91% of claims with no manual work.
The Oct. 30 grant sets up an FDA classification for electromechanical systems used in endoluminal surgery, with Virtuoso's endoscopy system the first in it. The Nashville company plans a focused rollout at U.S. urology centers in 2027.
Drive Capital led the Series B, joined by Sanofi Ventures, HealthX Ventures and Alumni Ventures. Zus, founded by athenahealth co-founder Jonathan Bush, has now raised more than $100 million.
Insight Partners led the Series B, bringing Charta's total to $85 million. The company is launching separate products for providers and health plans that it says share a single AI engine.
Norwest and SV Health Investors' MedTech Convergence Fund co-led the Series B, with Labcorp's venture fund taking part. The money funds manufacturing scale-up and the clinical study Nanopath needs for a 510(k) submission.
FDA cleared the Belfast startup's PulseAPI SmartWatch analysis library Oct. 27 under K254226. PulseAI said its focus now is getting the software into devices and platforms that millions of people already use.
The clinical trial data software company says it went nearly a decade without new equity. It plans to expand its AI tools for drug sponsors and contract research organizations and to grow globally.
Valtruis led the Series A, and Andreessen Horowitz, Foundry and CommonSpirit Ventures invested again. Midstream says its customers run more than 250 hospitals with over $100 billion in combined yearly operating costs.
FDA cleared the expanded use Oct. 13 under K261321, and the Miami company announced it Oct. 29. The filing relied on bench and human factors testing and added no new device capabilities for that use, according to FDA's summary.
Metis MedTech, the family office of John Slump, led the oversubscribed Series A. StimCardio says the money should carry it through a pivotal study and preparation of an FDA De Novo request for its nerve-stimulation wristband.
Threshold Ventures led the Series A for the 12-person San Francisco company, which grades medical evidence behind each answer. The product is free to clinicians, and the release does not say how Vera makes money.
The Oct. 21 clearance, K261252, adds hysterectomy and five other benign gynecologic procedures to a U.S. label that covered only gallbladder removal. Stryker agreed Oct. 12 to invest about $400 million and be its exclusive U.S. sales agent.
FirstMark Capital led the Series A, joined by CVS Health Ventures and Valtruis. The New York company says it has more than 100,000 families on a waiting list and was picked for all four tracks of CMS's ACCESS Model.
FDA approved Vivasure Medical's premarket application for the large-bore vascular closure device on Oct. 16. Haemonetics bought Vivasure in January for €100 million up front.
The Oct. 15 clearance, issued to DEKA Research and Development, extends the twiist Loop dosing algorithm to adults with insulin-treated type 2 diabetes. Sequel estimates the expansion adds about 5.5 million people in the U.S. who use insulin.
RA Capital led a $93 million Series A for the startup, which is built on Yale research and plans to start human testing of its first polycystic kidney disease program in 2027.
Avidity Partners led the Series D for the cloud radiology software company, which says revenue grew 2.5 times in a year and that it is contracted to onboard more than 1,000 additional radiologists.
A Form D filed Oct. 14 shows the Rockville, Md., autoimmune antibody developer sold nearly $55 million of a planned $73.4 million equity offering to 22 investors. Its newsroom shows no announcement of the raise.
Healthier Capital, Crosslink Capital and Hercules Capital joined the Series E. Suki says its revenue doubled last year and sales to companies that embed its AI have grown more than tenfold in two years.
Sequoia and First Round co-led an $8 million seed and Hummingbird led a $30 million Series A, TechCrunch reported. Healthleap's software flags inpatients for review; the company says it does not diagnose.
Oak HC/FT led the Series A for Vitalize, which sells AI scheduling and capacity software to health systems. The company says labor makes up 50% to 60% of what hospitals spend to operate.
A Form D filed Oct. 5 shows the maker of the MIRA surgical robot sold $35.1 million of a planned $80.1 million offering, almost all of it from converted notes. The company has not announced the round.
Cook Medical led Zenflow's oversubscribed $52 million Series D and will be the exclusive U.S. distributor of the Zenflow Spring, an in-office implant for enlarged prostate that the FDA approved in December 2025.
A Form D filed Oct. 1 shows the RTW-backed New York company sold $35 million of a planned $60 million equity offering to five investors. Amani has announced only one financing, a $25 million Series A in March.
The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.